COEP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
COEP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Coeptis Therapeutics Holdings's change in receivables for the quarter that ended in Mar. 2024 was $-0.07 Mil. It means Coeptis Therapeutics Holdings's Accounts Receivable increased by $0.07 Mil from Dec. 2023 to Mar. 2024 .
Coeptis Therapeutics Holdings's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.03 Mil. It means Coeptis Therapeutics Holdings's Accounts Receivable increased by $0.03 Mil from Dec. 2022 to Dec. 2023 .
Coeptis Therapeutics Holdings's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Coeptis Therapeutics Holdings's liquidation value for the three months ended in Mar. 2024 was $-4.01 Mil.
The historical data trend for Coeptis Therapeutics Holdings's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coeptis Therapeutics Holdings Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Change In Receivables | -0.02 | 0.02 | -0.01 | -0.03 |
Coeptis Therapeutics Holdings Quarterly Data | ||||||||||||||
Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Change In Receivables | Get a 7-Day Free Trial | 0.01 | - | - | -0.04 | -0.07 |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coeptis Therapeutics Holdings (NAS:COEP) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Coeptis Therapeutics Holdings's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0 | / | 0 | * | 91 |
= |
2. In Ben Graham's calculation of liquidation value, Coeptis Therapeutics Holdings's accounts receivable are only considered to be worth 75% of book value:
Coeptis Therapeutics Holdings's liquidation value for the quarter that ended in Mar. 2024 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 1.029 | - | 5.035 | + | 0.75 * 0 | + | 0.5 * 0 |
= | -4.01 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Coeptis Therapeutics Holdings's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Tara Desilva | director | 105 BRADFORD RD., SUITE 420, WEXFORD PA 15090 |
David Mehalick | director, 10 percent owner, officer: CEO and President | 5000 TRESSDALE DRIVE, GIBSONIA PA 15044 |
Christopher P. Cochran | director | 105 BRADFORD RD., SUITE 420, WEXFORD PA 15090 |
Gene Salkind | director | 1165 WRACK ROAD, MEADOWBROOK PA 19046 |
Daniel Alexander Yerace | director, officer: VP of Operations | 402 SCHOMBURG COURT, CRANBERRY TOWNSHIP PA 16066 |
Chris Calise | director, 10 percent owner, officer: Chief Financial Officer | 801 S. POINTE DRIVE SUITE TH-1, MIAMI BEACH FL 33139 |
Philippe Deschamps | director | 105 BRADFORD RD, SUITE 420, WEXFORD PA 15090 |
Christine Elise Sheehy | officer: CFO and Secretary | 206 TAMARACK DRIVE, MARS PA 16046 |
Harraden Circle Investments, Llc | 10 percent owner | 299 PARK AVE, 21ST FLOOR, NEW YORK NY 10171 |
Harraden Circle Investors Gp, Lp | 10 percent owner | 299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171 |
Harraden Circle Investors Gp, Llc | 10 percent owner | 299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171 |
Fortmiller Frederick Vincent Jr. | 10 percent owner | 151 LULL ROAD, NEW BOSTON NH 03070 |
Harraden Circle Investors, Lp | 10 percent owner | 299 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10171 |
Plc Barclays | 10 percent owner | 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP |
Paul J Glazer | 10 percent owner | 250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019 |
From GuruFocus
By PRNewswire • 10-04-2023
By PRNewswire PRNewswire • 06-16-2023
By PRNewswire • 09-27-2023
By PRNewswire • 09-11-2023
By PRNewswire PRNewswire • 03-21-2023
By PRNewswire PRNewswire • 04-18-2023
By PRNewswire • 09-14-2023
By PRNewswire PRNewswire • 11-15-2022
By PRNewswire PRNewswire • 05-10-2023
By PRNewswire • 12-04-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.